JG
PTGX icon

Jefferies Group’s Protagonist Therapeutics PTGX Stock Holding History

Jefferies Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$974K Buy
+115,500
New +$1.09M 0.01% 821
2020
Q1 		– Sell
-11,756
Closed -$83K – 2545
2019
Q4 		$83K Buy
+11,756
New +$117K ﹤0.01% 2406
2019
Q2 		– Sell
-14,100
Closed -$177K – 2810
2019
Q1 		$177K Buy
+14,100
New +$124K ﹤0.01% 1975

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Group's PTGX Position: Q3 2022 in Review

Jefferies Group opened a new position in Protagonist Therapeutics (PTGX) in Q3 2022: 115,500 shares worth $974K. The stake represents 0.01% of the portfolio and ranks #821 among its holdings. This is a return to the name: Jefferies Group previously reported a position in PTGX as recently as Q4 2019.

Jefferies Group first reported a position in PTGX in Q1 2019 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold PTGX as of Q3 2022.

  • Jefferies Group held 115,500 shares of Protagonist Therapeutics worth $974K as of Q3 2022.
  • Protagonist Therapeutics was a new Jefferies Group position in Q3 2022.
  • Protagonist Therapeutics made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #821 holding.
  • Jefferies Group first reported a position in Protagonist Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.